JP Morgan Downgrades Integra Lifesciences to Underweight, Lowers Price Target to $43
Portfolio Pulse from richadhand@benzinga.com
JP Morgan analyst Robbie Marcus downgraded Integra Lifesciences (NASDAQ:IART) from Neutral to Underweight and lowered the price target from $56 to $43.
May 24, 2023 | 9:19 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Integra Lifesciences downgraded to Underweight by JP Morgan, with a lowered price target of $43.
The downgrade from Neutral to Underweight and the lowering of the price target from $56 to $43 by JP Morgan analyst Robbie Marcus indicate a negative outlook for Integra Lifesciences. This could lead to a short-term decline in the stock price as investors may adjust their positions based on the new rating and price target.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100